Parasite protein injection aims to tame Crohn's Flare-Ups
NCT ID NCT02281916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the safety of P28GST, a protein from a parasite, in 10 adults with moderate Crohn's disease. Participants received three injections over three months. The goal was to see if the protein could safely control inflammation, especially after intestinal surgery. The study is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
P28GST (a protein from a parasite, given as an injection)
What this could lead to
If it works, this could point toward a new way to control inflammation in Crohn's disease without long-term side effects.
What could go wrong
This is a very small, early-phase safety study with only 10 people. It is not designed to prove effectiveness, and the approach is experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S ILEOCOLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU, Hôpital Claude Huriez
Lille, 59037, France
-
Centre Hospitalier Dunkerque
Dunkirk, France
-
Centre Hospitalier de Boulogne
Boulogne-sur-Mer, France
-
Centre Hospitalier,
Valenciennes, France
-
Centre hospitalier
Amiens, France